iX Biopharma Ltd. (SGX:42C)
Singapore
· Delayed Price · Currency is SGD 0.1160
+0.0050 (4.50%)
Dec 5, 2025, 5:04 PM SGT
iX Biopharma Cash Flow Statement
Financials in millions SGD. Fiscal year is July - June.
Millions SGD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| Net Income | -10.14 | -10.79 | -9.62 | -4.6 | -8.23 | Upgrade
|
| Depreciation & Amortization | 0.85 | 0.86 | 0.89 | 1.01 | 1 | Upgrade
|
| Other Amortization | 0 | 0.01 | 0.04 | 0.05 | 0.05 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | - | -0 | Upgrade
|
| Loss (Gain) From Sale of Investments | 0.01 | 2.51 | -1.74 | 3.26 | - | Upgrade
|
| Stock-Based Compensation | 0.03 | -0.85 | 0.86 | 1.38 | 1 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 0.11 | - | - | - | Upgrade
|
| Other Operating Activities | 4.57 | 1.46 | 2.36 | 2.72 | -1.84 | Upgrade
|
| Change in Accounts Receivable | 0.08 | -0.11 | -0.85 | -0.23 | 0.02 | Upgrade
|
| Change in Inventory | 0.31 | -0.62 | -0.2 | -0.04 | -0.35 | Upgrade
|
| Change in Accounts Payable | 0.48 | 0.86 | 0.71 | -0.27 | -0.07 | Upgrade
|
| Change in Other Net Operating Assets | 0.06 | 0 | -0.12 | -0.16 | 0.07 | Upgrade
|
| Operating Cash Flow | -3.76 | -6.55 | -7.66 | 3.12 | -8.35 | Upgrade
|
| Capital Expenditures | -0.2 | -0.27 | -0.7 | -0.2 | -0.55 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 1.34 | - | - | 0.05 | Upgrade
|
| Sale (Purchase) of Intangibles | - | -0.01 | - | - | - | Upgrade
|
| Investment in Securities | - | - | - | -5.42 | - | Upgrade
|
| Investing Cash Flow | -0.2 | 1.06 | -0.7 | -5.62 | -0.51 | Upgrade
|
| Long-Term Debt Issued | 1.51 | 2.03 | - | 1.4 | - | Upgrade
|
| Long-Term Debt Repaid | -1.05 | -1.02 | -0.99 | -1.02 | -0.6 | Upgrade
|
| Net Debt Issued (Repaid) | 0.46 | 1.01 | -0.99 | 0.37 | -0.6 | Upgrade
|
| Issuance of Common Stock | 3.25 | - | 2.73 | 9.62 | 10.18 | Upgrade
|
| Other Financing Activities | -0.59 | -0.29 | -0.31 | -0.2 | 0.45 | Upgrade
|
| Financing Cash Flow | 3.12 | 0.72 | 1.42 | 9.79 | 10.02 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.01 | - | -0.05 | 0.03 | -0.05 | Upgrade
|
| Net Cash Flow | -0.83 | -4.77 | -6.98 | 7.32 | 1.12 | Upgrade
|
| Free Cash Flow | -3.96 | -6.83 | -8.36 | 2.92 | -8.91 | Upgrade
|
| Free Cash Flow Margin | -50.97% | -114.57% | -141.30% | 20.31% | -510.32% | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 | Upgrade
|
| Cash Interest Paid | 0.68 | 0.32 | 0.27 | 0.2 | 0.17 | Upgrade
|
| Cash Income Tax Paid | -0.73 | -0.48 | -0.54 | -0.71 | -0.72 | Upgrade
|
| Levered Free Cash Flow | -1.86 | -5 | -6.58 | 3.76 | -6.46 | Upgrade
|
| Unlevered Free Cash Flow | -1.66 | -4.72 | -6.41 | 3.89 | -6.36 | Upgrade
|
| Change in Working Capital | 0.93 | 0.14 | -0.45 | -0.7 | -0.33 | Upgrade
|
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.